Bernstein Keeps Their Hold Rating on Agilon Health (AGL)
Truist Financial Maintains Agilon Health(AGL.US) With Hold Rating
BofA Securities Maintains Agilon Health(AGL.US) With Sell Rating, Announces Target Price $2.4
Agilon Health Faces Financial Challenges Amid Rising Costs and Enrollment Risks: Analyst Recommends Sell Rating
Benchmark Co. Maintains Agilon Health(AGL.US) With Buy Rating, Cuts Target Price to $4
Barclays Maintains Agilon Health(AGL.US) With Sell Rating, Maintains Target Price $2
Agilon Health (AGL) Receives a Sell From Barclays
Analysts Conflicted on These Healthcare Names: Agilon Health (AGL), AN2 Therapeutics, Inc. (ANTX) and Alcon (ALC)
Cautious Hold Rating on Agilon Health Amid Uncertainty and Cost Challenges
Agilon Health Is Maintained at Outperform by RBC Capital
Agilon Health Is Maintained at Hold by Stifel
Truist Financial Maintains Agilon Health(AGL.US) With Hold Rating
TD Cowen Sticks to Their Hold Rating for Agilon Health (AGL)
A Quick Look at Today's Ratings for Agilon Health(AGL.US), With a Forecast Between $5 to $5
Agilon Health Analyst Ratings
RBC Raises Price Target on Agilon Health to $3.50 From $3, Keeps Outperform Rating
Analysts Offer Insights on Healthcare Companies: AxoGen (AXGN), Agilon Health (AGL) and LAVA Therapeutics (LVTX)
William Blair Remains a Hold on Agilon Health (AGL)
Bernstein Maintains Market Perform on Agilon Health, Raises Price Target to $3.15
Agilon Health Analyst Ratings